Abstract 1622P
Background
KRAS mutations are found in approximately 90% of PCa, of which 1-2% are KRAS G12C. D-1553 has shown clinical activity in patients (pts) with KRAS G12C mutated non-small cell lung cancer and colorectal cancer. Here, we report preliminary data of D-1553 in KRAS G12C mutated advanced PCa.
Methods
Pts with KRAS G12C mutated advanced PCa (with no standard treatment available or refractory or intolerant to existing standard treatment) were enrolled and received D-1553 at the recommended phase II dose of 600 mg BID orally. Study endpoints included safety, pharmacokinetics (PK), and efficacy (RECIST, v1.1). Efficacy endpoints included objective response, disease control (defined as an objective response or stable disease) and progression-free survival. Safety was also assessed.
Results
As of 01 March 2023, a total of 10 pts with advanced PCa (median age 67.5 years [range 48–78]; 60% female; 70% Asian; 80%/20% ECOG PS 0/1; 100% stage IV disease at baseline; 40% with ≥ 2 prior lines of therapy [median 1]) were enrolled and treated with D-1553. At data cutoff, 5 (50%) pts remained on treatment. The median duration of treatment and follow-up were 7.15 months (range 1.22-8.94) and 8.10 (range 4.47-9.23) months, respectively. The objective response rate was 50.0% (5/10, including 1 confirmed complete response, 3 confirmed partial response [PR], and 1 unconfirmed PR) and disease control rate was 80.0% (8/10). Median progression-free survival was 8.54 (95% CI 1.25-NA) months. Treatment-related adverse events (TRAEs) of any grade occurred in 7 (70.0%) pts, with the most commonly (≥ 20%) reported as increased ALT, increased AST, decreased appetite, and diarrhoea. Grade 3 TRAEs occurred in 2 (20%) pts, including increased ALT, increased AST and increased alkaline phosphatase. There was no grade > 3 TRAEs, nor TRAEs leading to death or D-1553 permanent discontinuation.
Conclusions
D-1553 is well tolerated and has shown promising anticancer activity in pts with pre-treated KRAS G12C mutated advanced PCa. This study is ongoing, and more results will be presented at the meeting.
Clinical trial identification
NCT04585035, NCT05383898.
Editorial acknowledgement
Legal entity responsible for the study
InventisBio Co., Ltd.
Funding
InventisBio Co., Ltd.
Disclosure
S. Kondo: Financial Interests, Institutional, Speaker’s Bureau: Abbie; Financial Interests, Institutional, Research Grant: Eisai, Astellas, Incyte, AstraZeneca, Daiichi Sankyo; Financial Interests, Personal, Speaker’s Bureau: Incyte, Chugai, Eisai. X. Liu, Y. Zhang, X. Xie: Financial Interests, Personal, Full or part-time Employment: InventisBio. Z. Xiang, Z. Shi, Y. Wang, L. Zhang: Financial Interests, Personal, Full or part-time Employment: InventisBio; Financial Interests, Personal, Stocks/Shares: InventisBio. N. Yamamoto: Financial Interests, Personal, Invited Speaker: Ono, Chugai, Daiichi Sankyo, Eisai; Financial Interests, Personal, Advisory Board: Eisai, Takeda, Boehringer Ingelheim, Cimic, Chugai, Healios; Financial Interests, Institutional, Invited Speaker, Principal Investigator in industry sponsored trial: Astellas, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi Sankyo, Bayer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Takeda, Ono, Janssen Pharma, MSD, Merck, GSK, Sumitomo Dainippon, Chiome Bioscience, Otsuka; Financial Interests, Institutional, Invited Speaker, Principal investigator in industry sponsored trial: Carna Biosciences, Genmab, Shionogi, Toray; Financial Interests, Institutional, Research Grant, Principal investigator in industry sponsored trial: Rakuten Medical, InventisBio Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
1645P - STAT3, ACTA2, and SPARC stromal markers predict response to Gemcitabine/Cisplatin/Nab-paclitaxel (GCN) in patients with advanced pancreatic adenocarcinoma (apdac)
Presenter: Himil Mahadevia
Session: Poster session 22
1646P - Genomic and prognostic differences in patients with different KRAS mutations in pancreatic cancer
Presenter: Chunwei Xu
Session: Poster session 22
1647P - Cancer-associated endocrine cell: A novel component of tumor microenvironment in pancreatic cancer
Presenter: Yuan Chen
Session: Poster session 22
1648P - Association between circulating tumor cell count and thrombosis in pancreatic cancer
Presenter: Monica Benavente
Session: Poster session 22
1649P - Comprehensive genomic profiling contributes to the prognosis of patients with advanced pancreatic cancer
Presenter: Eiichiro So
Session: Poster session 22
1650P - Identification of potential targets in pancreatic adenocarcinoma: The KRAS Wild-Type subset
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1651P - Comparison of surgical outcome and prognostic factors between pancreaticobiliary and intestinal types of periampullary adenocarcinoma following pancreaticoduodenectomy
Presenter: Saad Anwar
Session: Poster session 22
1652P - Interaction between enhanced cytokine signalling and ferroptosis defence fuels obesity-associated pancreatic ductal adenocarcinoma oncogenesis
Presenter: Rishat Ruzi
Session: Poster session 22
1653P - The activated thermogenesis of intra-pancreatic fat fuels the progression of pancreatic cancer
Presenter: Xi'n'peng Yin
Session: Poster session 22
1654P - Circulating tumor cells (CTCs) as prognostic factor for pancreatic cancer: Updated of a prospective study
Presenter: Natalia Gutierrez Alonso
Session: Poster session 22